TAVO423 is a FAP × LRRC15 × HYAL trispecific AbEn that effectively degraded HA, delayed tumor growth, and enhanced the efficacy of various therapeutics in an in vivo HA-rich colorectal cancer model. This evidence concerns the gene LRRC15 and colorectal cancer.